PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.

Slides:

Advertisements

Similar presentations

S2 Fig. Phenotype of donor cells in the spleen and bone marrow of male mice. Splenocytes and bone marrow were isolated from male donor mice and stained.

Advertisements

AF647-RIS is internalized by TAMs in vivo.

Synergistic antitumor effect of anti-CD40/CpG and 14

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Early studies evaluating role of immune infiltrate in colorectal cancer

Nat. Rev. Clin. Oncol. doi: /nrclinonc

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Fig. 5 A competent Fc is required for the antitumor immune response.

Functions of myeloid cells.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

The absence of ADCC by nivolumab in vitro.

Immune cell populations, activation, and NKG2D and H60a expression in the spleen of untreated and antibiotic-treated Klrk1+/+ and Klrk1−/− NOD mice. Immune.

Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor

1 Oncomine database: DKK2 upregulation in colorectal cancers(CRC)

Fig. 4 Surgery initiates a systemic inflammatory response that triggers the outgrowth of distant immunogenic tumors and can be inhibited by perioperative.

Fig. 6 Innate and adaptive immunity, but not ADCC, contributes to M7824 antitumor activity. Innate and adaptive immunity, but not ADCC, contributes to.

Fig. 4. Dabrafenib and trametinib changed the cellular components of the tumor microenvironment. Dabrafenib and trametinib changed the cellular components.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Michele De Palma, Rakesh K. Jain Immunity

Distribution of splenic T cells, B cells, and NK cells in NSG hL-7xhIL-15 humanized mice. Distribution of splenic T cells, B cells, and NK cells in NSG.

Socs1 KD tumors show alterations in multiple populations.

Effect of increasing pantetheinase activity in R tumors.

PhenoGraph-based visualization on tSNE plots.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Fig. 5 A competent Fc is required for the antitumor immune response.

NOX1-deficient mice do not respond to GKT771 and exhibit reduced B16-F10 tumor growth associated with decreased production of angiogenic factors and minor.

NOX1-deficient mice do not respond to GKT771 and exhibit reduced tumor growth, angiogenesis, and lymphangiogenesis. NOX1-deficient mice do not respond.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

Anti-PD-1H Antibody Prevents Graft Versus Host Disease

Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.

CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Geographic colocalization of PD-L1+ tumor cells with infiltrating immune cells in MCC. The predominant pattern of tumor cell PD-L1 expression is at the.

Possible mechanisms of recognition of MHCIlow tumor cells by NSCs

Flow cytometric analysis of T cell activation.

In vivo thrombosis of tumor vasculature.

Rapamycin decreases PD-L1 expression in lung tumors in vivo.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

5FU-induced specific activation of CD8+ T cells.

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.

Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. Correlation of PTEN loss in melanoma cells with an immune resistance phenotype.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

Immune response of CEA-transgenic mice transferred with OT-1 splenocytes and immunized with ovalbumin and adjuvant. Immune response of CEA-transgenic mice.

Anti–TGF-β1 antibody neutralizes APB-mediated immune suppression.

LSECtin, expressed by B16 cells, inhibits the tumor-specific immune responses both in vivo and in vitro. LSECtin, expressed by B16 cells, inhibits the.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

Hypoxia upregulates CD137 expression in T lymphocytes undergoing activation. Hypoxia upregulates CD137 expression in T lymphocytes undergoing activation.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

Ex vivo profiling of PD-1 blockade using MDOTS

IL2Cx alone or in combination with anti–CTLA-4 increases the CD8/Treg ratio in the tumor. IL2Cx alone or in combination with anti–CTLA-4 increases the.

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.

Antiangiogenic effects of PI3K inhibitor NVP-BKM120.

Phenotyping of T cells. Phenotyping of T cells. Circulating lymphocytes from a tumor-naïve C57BL/6 mice (left column) were compared with those from C57BL/6.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Presentation transcript:

PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38 tumors in C57/BL6 mice treated with GKT771, anti-PD1 antibody, a combination thereof, and the corresponding controls. (A) The cells were isolated from tumors and stained with antibodies for CD45, CD11b, F4/80, and CD68. (A) Ratios of CD45+/CD11b+/CD68+/F4/80+ and CD45+/CD11b+/CD68+/F4/80− TAMs. (B) Ratios of CD45+/CD11b+/F4/80+ and CD45+/CD11b+/F4/80− macrophages. Jimmy Stalin et al. LSA 2019;2:e201800265 © 2019 Stalin et al.